



25 February 2019

**RENOUNCEABLE PRO-RATA RIGHTS ISSUE – Close of Offer and Shortfall notification**

Neurotech International Limited (ASX: **NTI**) (**Neurotech** or **Company**) refers to its announcement of 29 January 2019 in relation to a Renounceable Pro-rata Rights Issue offer of shares and free attaching options (**Rights Issue**) to eligible shareholders and associated Shortfall offer (**Shortfall Offer**), pursuant to the Prospectus dated 29 January 2019 (**Offers**).

The Offers closed on Wednesday 20 February 2019 at 5.00pm WST, with the Company receiving applications for 26,122,966 shares to raise \$783,689 (before costs), representing 23,521,466 shares applied for under the Rights Issue and 2,601,500 shares applied for under the Shortfall Offer. One free attaching option, exercisable at \$0.06 on or before 31 March 2021, will be issued for every new share.

All Directors of the Company who were eligible to participate in the Rights issue, including their related entities, applied for shares and options under the Rights Issue offer.

As stated in the Prospectus, the Company has reserved the right to place the remaining shortfall to the Rights Issue offer within 3 months from closure of the Offers.

The Company will issue the 26,122,966 shares and 26,122,966 options, and dispatch holding statements to shareholders, on Monday 25 February 2019. The Company has applied to the ASX for quotation of the new options.

-ends-

---

**Neurotech International Ltd**

ABN 73 610 205 402

Level 14, 225 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

## **About Neurotech**

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420